What Is and Is Not in Trump's Drug Pricing Plan: An Interview With Dr Michael Chernew

American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.

American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.

Mary Caffrey, the managing editor of The American Journal of Managed Care® (AJMC®)s Evidence-Based series, spoke with Harvard healthcare economist Michael E. Chernew, PhD, who is the co-editor in chief of AJMC®, to discuss elements of the Trump administration proposal to control drug prices. Chernew is also a former vice chair of the Medicare Payment Advisory Commission.

To listen, login to the website.